Dewan Smith-Williams
Psychiatric/Mental Health · Fairlawn, OHNPI 1851831556
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 670 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $5,239 and has fallen 95.2% since, to $251 in 2025. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 670 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$1K
- Lundbeck LLC$1K
- Supernus Pharmaceuticals, Inc.$973
- plus $6K from 22 others
What the payments were for
- Consulting fees$1151%
- Speaking & faculty fees$1,0648%
- Food & beverage$12,55191%
- Education$1351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 38 | $1,729 |
| AbbVie | 82 | $1,587 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 66 | $1,510 |
| Alkermes, Inc. | 52 | $1,250 |
| Lundbeck LLC | 78 | $1,187 |
| Supernus Pharmaceuticals, Inc. | 92 | $973 |
| Axsome Therapeutics, Inc. | 23 | $664 |
| Teva Pharmaceuticals USA, Inc. | 31 | $625 |
| Indivior Inc. | 38 | $603 |
| Johnson & Johnson | 21 | $581 |
| Neurocrine Biosciences, Inc. | 29 | $557 |
| Vanda Pharmaceuticals Inc. | 16 | $437 |
| Corium, LLC | 23 | $382 |
| E.r. Squibb & Sons, L.L.C. | 8 | $267 |
| Idorsia Pharmaceuticals US Inc | 8 | $236 |
| Almatica Pharma LLC | 12 | $232 |
| Eisai Inc. | 8 | $154 |
| Sunovion Pharmaceuticals Inc. | 14 | $145 |
| Validus Pharmaceuticals LLC | 3 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| Braeburn Inc. | 7 | $115 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Noven Therapeutics, LLC | 6 | $107 |
| Merck | 3 | $52 |
| Neuronetics, Inc. | 2 | $35 |
| Orexo US, Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,865 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $155,386 |
| SpravatoEsketamine Hcl | 24 | $133,468 |
| VraylarCariprazine Hcl | 69 | $96,161 |
| RexultiBrexpiprazole | 45 | $64,337 |
| Invega SustennaPaliperidone Palmitate | 26 | $60,818 |
| AuvelityDextromethorphan Hbr/Bupropion | 48 | $51,450 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $39,646 |
| Lurasidone Hcl | 47 | $34,122 |
| TrintellixVortioxetine Hydrobromide | 49 | $25,112 |
| Asenapine Maleate | 109 | $20,752 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 35 | $6,611 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 172 | $4,684 |
| Aripiprazole | 26 | $2,922 |
| Alprazolam | 266 | $2,616 |
| Oxcarbazepine | 41 | $2,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $581 | $194,28650 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $557 | $155,38620 claims |
| AbbVieVraylar | $1,587 | $96,16169 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,729 | $64,33745 claims |
| Axsome Therapeutics, Inc.Auvelity | $664 | $51,45048 claims |
| Alkermes, Inc.Lybalvi | $1,250 | $39,64628 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $126 | $25,11249 claims |
| Almatica Pharma LLCSertraline Hcl | $232 | $40257 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Fairlawn
- Mark GarretsonFairlawn$14K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.